BACKGROUND: There is a lack of studies on methamphetamine (MA) exposure and morbidity in children beyond the perinatal period. OBJECTIVES: We compared morbidity in children (0-3 years) with prenatal MA exposure to opioid-exposed and to non-exposed children. METHODS: We used data from a Czech nationwide, registry-based cohort study (2000-2014). Children, who reached 3 years of age, of mothers hospitalized with (i) MA use disorder during pregnancy (MA; n = 194), (ii) opioid use disorder during pregnancy (opioids; n = 166), and (iii) general population (GP; n = 1,294,349) with no recorded history of substance use disorder (SUD). Information on inpatient contacts, length of stay, and diagnoses (International Statistical Classification of Diseases and Related Health Problems 10th Revision [ICD-10]) were assessed. Crude and adjusted odds ratios (aOR), 95% confidence interval (CI) for the risk of hospitalization, and for getting diagnosis from the ICD-10 diagnosis chapters were calculated using binary logistic regression. A stratified analysis on hospitalizations with SUD of mothers was performed. RESULTS: No significant differences were found in the measures of hospitalization between the MA and opioid groups. Children prenatally exposed to MA and opioids had higher numbers of hospitalizations and diagnoses and longer stays in hospital than children in the GP. Increased risks of certain infectious and parasitic diseases were found in both MA (aOR = 1.6; CI: 1.1-2.3) and opioid (aOR = 1.9; 1.3-2.8) groups as compared to the GP group. The most pronounced difference in stratified analysis on maternal hospitalizations related to SUD after birth was observed for injury, poisoning, and certain other consequences of external causes in the strata of the MA group who had hospitalized mothers (aOR 6.3, 1.6-24.6) compared to the strata without maternal hospitalizations (aOR 1.4, 0.9-2.3). CONCLUSION: This study suggests that children born to mothers using MA during pregnancy have similar morbidity during the first 3 years of life but higher than the GP. The excess of risk was primarily due to infections and injuries in the MA group.

Department of Addictology 1st Faculty of Medicine Charles University Prague Czechia

Department of Addictology General University Hospital Prague Prague Czechia

Norwegian Centre for Addiction Research at the University of Oslo Oslo Norway

Norwegian Institute of Public Health Oslo Norway

See more in PubMed

Abdel-Latif ME, Oei J, Craig F, Lui K, NSW and ACT NAS Epidemiology Group Profile of infants born to drug-using mothers: a state-wide audit. J Paediatr Child Health. 2013;49((1)):E80–E86. PubMed

Derauf C, Katz AR, Frank DA, Grandinetti A, Easa D. The prevalence of methamphetamine and other drug use during pregnancy in Hawaii. J Drug Issues. 2003;33((4)):1001–1016.

Arria AM, Derauf C, LaGasse LL, Grant P, Shah R, Smith L, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006;10((3)):293–302. PubMed

Della Grotta S, LaGasse LL, Arria AM, Derauf C, Grant P, Smith LM, et al. Patterns of methamphetamine use during pregnancy: results from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2010;14((4)):519–527. PubMed PMC

Smid MC, Metz TD, Gordon AJ. Stimulant use in pregnancy: an under-recognized epidemic among pregnant women. Clin Obstet Gynecol. 2019;62((1)):168–184. PubMed PMC

Diaz SD, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, et al. Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. J Pediatr. 2014;164((6)):1333–1338. PubMed PMC

LaGasse LL, Derauf C, Smith LM, Newman E, Shah R, Neal C, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics. 2012;129((4)):681–688. PubMed PMC

Billing L, Eriksson M, Larsson G, Zetterström R. Amphetamine addiction and pregnancy. III One year follow-up of the children. Psychosocial and pediatric aspects. Acta Paediatr Scand. 1980;69((5)):675–680. PubMed

Billing L, Eriksson M, Steneroth G, Zetterström R. Predictive indicators for adjustment in 4-year-old children whose mothers used amphetamine during pregnancy. Child Abuse Negl. 1988;12:503–507. PubMed

Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterström R. Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr. 1996;85((2)):204–208. PubMed

Derauf C, LaGasse LL, Smith LM, Grant P, Shah R, Arria A, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the Infant Development, Environment, and Lifestyle Study (IDEAL) Am J Drug Alcohol Abuse. 2007;33((2)):281–289. PubMed PMC

Kiblawi ZN, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, et al. The effect of prenatal methamphetamine exposure on attention as assessed by continuous performance tests: results from the infant development, environment, and lifestyle study. J Develop Behav Pediatr. 2013;34((1)):31–37. PubMed PMC

Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Haning W, et al. Motor and cognitive outcomes through 3 years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol. 2011;33((1)):176–184. PubMed PMC

Skurtveit S, Nechanská B, Handal M, Mahic M, Mravčík V, Gabrhelík R. Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic. Addiction. 2019;114((7)):1225–1235. PubMed PMC

Oei JL, Kingsbury A, Dhawan A, Burns L, Feller JM, Clews S, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol. 2012;32((10)):737–747. PubMed

Mravčík V, Nechanská B, Gabrhelík R, Handal M, Mahic M, Skurtveit S. Socioeconomic characteristics of women with substance use disorder during pregnancy and neonatal outcomes in their newborns: a national registry study from the Czech Republic. Drug Alcohol Depend. 2020;209:107933. PubMed

Gabrhelík R, Skurtveit S, Nechanská B, Handal M, Mahic M, Mravčík V. Prenatal methamphetamine exposure and adverse neonatal outcomes: a nationwide cohort study. Eur Addict Res. 2021;27((2)):97–106. PubMed

Gabrhelík R, Nechanská B, Mravčík V, Skurtveit S, Lund IO, Handal M. A unique opportunity to study short- and long-term consequences in children prenatally exposed to illicit drugs and opioid maintenance treatment using Czech and scandinavian registers. Cent Eur J Public Health [Internet] 2016 [cited 2019 Mar 9];24((3)):248–251. PubMed

Minařík J, Gabrhelík R, Malcolm R, Pavlovská A, Miller P. Methylphenidate substitution for methamphetamine addiction and implications for future randomized clinical trials: a unique case series. J Subst Use. 2016;21((4)):435–438.

European Monitoring Centre for Drugs and Drug Addiction . European drug report 2019. Trends and Developments; 2019. [cited 2019 Aug 17]. Available from: https://data.europa.eu/doi/10.2810/191370. DOI

Londero AP, Rossetti E, Pittini C, Cagnacci A, Driul L. Maternal age and the risk of adverse pregnancy outcomes: a retrospective cohort study. BMC Pregnancy Childbirth. 2019;19((1)):261. PubMed PMC

Cantarutti A, Franchi M, Monzio Compagnoni M, Merlino L, Corrao G. Mother's education and the risk of several neonatal outcomes: an evidence from an Italian population-based study. BMC Pregnancy Childbirth. 2017;17((1)):221. PubMed PMC

Magnus MC, Wilcox AJ, Morken N-H, Weinberg CR, Håberg SE. Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study. BMJ. 2019;364:l869. PubMed PMC

Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res. 2018;35((3)):46. PubMed

Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT, et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics. 2017;139((6)):e20164131. PubMed PMC

Brenza J, Gabrhelík R. Use of opioid and stimulant medications in the Czech socialist republic before the “discovery” of the clandestine manufacturing of locally-specific stimulants and opiates. Adiktologie. 2014;14:284–293. http://199757.w57.wedos.ws/wp-content/uploads/2018/09/2014_3_Brenza_Vyvoj-uzivani-leciv.pdf .

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Tion Leštinová Z, Rous Z, et al. Výroční zpráva o stavu ve věcech drog v České republice v roce 2016. Prague: Úřad vlády České republiky; 2017. https://www.drogy-info.cz/publikace/vyrocni-zpravy/vyrocni-zprava-o-stavu-ve-vecech-drog-v-ceske-republice-v-roce-2017/

Greenland S. The effect of misclassification in the presence of covariates. Am J Epidemiol. 1980;112((4)):564–569. PubMed